|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,901.50 GBX | +0.16% |
|
+1.52% | +4.19% |
| 05-20 | GSK Begins Negotiations for Multiple Myeloma Treatment in Canada | MT |
| 05-20 | GSK, Pan-Canadian Pharmaceutical Alliance Start Talks for Blenrep to Treat Blood Cancer | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 102B | |||||
| 909B | |||||
| 552B | |||||
| 375B | |||||
| 332B | |||||
| 291B |
- Stock Market
- Equities
- GSK Stock
- Charts GSK plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition